Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jun 7, 2014; 20(21): 6386-6399
Published online Jun 7, 2014. doi: 10.3748/wjg.v20.i21.6386
Published online Jun 7, 2014. doi: 10.3748/wjg.v20.i21.6386
Helicobacter pylori infection: New pathogenetic and clinical aspects
Krisztina Hagymási, Zsolt Tulassay, 2nd Department of Internal Medicine, Semmelweis University, H-1088 Budapest, Hungary
Author contributions: Hagymási K and Tulassay Z drafted and wrote the manuscript; all authors read and approved the final manuscript.
Correspondence to: Krisztina Hagymási, MD, PhD, 2nd Department of Internal Medicine, Semmelweis University, H-1088 Budapest, Hungary. hagymasi.krisztina@med.semmelweis-univ.hu
Telephone: +36-1-2660926 Fax: +36-1-2664616
Received: September 28, 2013
Revised: January 5, 2014
Accepted: February 26, 2014
Published online: June 7, 2014
Processing time: 250 Days and 19.9 Hours
Revised: January 5, 2014
Accepted: February 26, 2014
Published online: June 7, 2014
Processing time: 250 Days and 19.9 Hours
Core Tip
Core tip:Helicobacter pylori (H. pylori) infects more than half of the world’s human population. The association between H. pylori infection and chronic active gastritis, peptic ulcer disease, gastric cell carcinoma, and B cell mucosa-associated lymphoid tissue lymphoma, unexplained iron deficiency anemia and idiopathic thrombocytopenic purpura has been well established. H. pylori screening and treatment is a recommended gastric cancer risk reduction strategy in high-risk populations. The unpredictability of the long-term consequences of H. pylori infection and the economic challenge in eradicating it is why identification of high-risk individuals is crucial.